▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #27 by analyst upside · 2026-09-27
GOVX
GeoVax Labs, Inc.
Healthcare · Market Cap $3M · P/E 0x
ANALYST PRICE TARGET
+2749.0%
implied upside to consensus target
Current Price $0.35
Consensus Target $10.0
Bull Target $10.0
Bear Target $10.0
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $0.35
52-Week High $16.8
YTD Return -93.2%
FUNDAMENTALS
Market Cap $3M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-5.62
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.35
52-Week High $16.8
Current Price $0.35
Bear Target $10.0
Bull Target $10.0
● Now $0.35 ● Target $10.0
TRADING DATA
Avg Volume 576K
YTD Return -93.2%
Analyst Count 2
Consensus Buy
Upside to Target +2749.0%
Last Updated 2026-09-27

ANALYST SUMMARY

GeoVax Labs, Inc. (GOVX) is currently trading at $0.35 with a Wall Street consensus price target of $10.0, implying potential upside of 2749.0% over the next 12 months. 2 analysts currently cover GOVX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $10.0, while the most cautious has a target of $10.0.

GOVX operates in the Healthcare sector with a market capitalisation of $3M. The stock is down 93.2% year-to-date and is currently trading near the lower end of its 52-week range of $0.35 – $16.8.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CNSY +1533.2%
Cerenome, Inc.
$15M · P/E 0.7x · Buy
TOVX +1033.3%
Theriva Biologics, Inc.
$10M · P/E 0.2x · Strong Buy
GTBP +988.5%
GT Biopharma, Inc.
$12M · P/E 0.1x · Buy
ETST +974.6%
Earth Science Tech, Inc.
$27M · P/E 9.3x · Hold
DWTX +929.4%
Dogwood Therapeutics, Inc.
$46M · P/E 0.7x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for GOVX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Noble Capital Markets - Reiterated
Outperform → Outperform 2026-09-15 Building track record
D. Boral Capital - Reiterated
Hold → Hold 2026-04-16 32% win rate (25 calls)
D. Boral Capital ↓ Downgrade
Buy → Hold 2026-02-19 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2026-01-21 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2025-11-19 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2025-09-26 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2025-08-07 32% win rate (25 calls)
D. Boral Capital - Reiterated
Buy → Buy 2025-07-29 32% win rate (25 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
8/30
Consensus clarity
8/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →